N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012

Oncoscience

Volumn 2, Issue 3, 2015, Pages 285-293

  Garrido Laguna, Ignacio ^a   Tometich, Danielle ^a   Hu, Nan ^a   Ying, Jian ^a   Geiersbach, Katherine ^a   Whisenant, Jonathan ^b   Wang, Kai ^c   Ross, Jeffrey S ^c,d   Sharma, Sunil ^a  

^a UNIVERSITY OF UTAH   (United States)

^b Utah Cancer Specialists ^*  (United States)

^c FOUNDATION MEDICINE   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

Author keywords

CRKL amplification; First in man studies; N of 1; Pancreatic cancer

Indexed keywords

EID: 84958552078     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.141     Document Type: Article

References (38)

1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29.
2. Hoos WA, James PM, Rahib L, Talley AW, Fleshman JM and Matrisian LM. Pancreatic cancer clinical trials and accrual in the United States. J Clin Oncol. 2013; 31(27):3432-3438.
3. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010; 362(17):1605-1617.
4. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-1825.
5. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18):1691-1703.
6. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C and de Gramont A. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005; 23(15):3509-3516.
7. Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, Gorner M, Molle M, Greten TF, Lakner V, Bischoff S, Sinn M, Dorken B and Pelzer U. Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial. J Clin Oncol. 2014; 32(23):2423-2429.
8. Gill S, Ko YJ, Cripps MC and al. e. PANCREOX: A randomized phase 3 study of 5FU/LV with our without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol Vol 32, N 15 (May 20 Supplement): 4022. 2014.
9. Von Hoff D, Li, C.P., Wang-Gillam, A. NAPOLI-1: Randomized Phase 3 Study of MM-398 (nal-IRI), With or Without 5-Fluoruracil and Leucovorin versus 5-Fluoruracil and Leucovorin, in Metastatic Pancreatic Cancer Progressed on or Following Gemcitabine-Based Therapy. Annals of Oncology 25 (2): ii105-ii117. 2014.
10. Abrams J, Conley B, Mooney M, Zwiebel J, Chen A, Welch JJ, Takebe N, Malik S, McShane L, Korn E, Williams M, Staudt L and Doroshow J. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book. 2014:71-76.
11. Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, Wheler J and Kurzrock R. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res. 2010; 16(4):1289-1297.
12. Gupta S, Hunsberger S, Boerner SA, Rubinstein L, Royds R, Ivy P and LoRusso P. Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. J Natl Cancer Inst. 2012; 104(24):1860-1866.
13. Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, Shoemaker D, Emanuel EJ and Grady C. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med. 2005; 352(9):895-904.
14. Roberts TG, Jr., Goulart BH, Squitieri L, Stallings SC, Halpern EF, Chabner BA, Gazelle GS, Finkelstein SN and Clark JW. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA. 2004; 292(17):2130-2140.
15. Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C and Messersmith WA. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res. 2012; 18(4):1092-1100.
16. Banerji U, van Doorn L, Papadatos-Pastos D, Kristeleit R, Debnam P, Tall M, Stewart A, Raynaud F, Garrett MD, Toal M, Hooftman L, De Bono JS, Verweij J and Eskens FA. A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012; 18(9):2687-2694.
17. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012; 13(8):773-781.
18. Kim YH, Kwei KA, Girard L, Salari K, Kao J, Pacyna-Gengelbach M, Wang P, Hernandez-Boussard T, Gazdar AF, Petersen I, Minna JD and Pollack JR. Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer. Oncogene. 2010; 29(10):1421-1430.
19. Cheung HW, Du J, Boehm JS, He F, Weir BA, Wang X, Butaney M, Sequist LV, Luo B, Engelman JA, Root DE, Meyerson M, Golub TR, Janne PA and Hahn WC. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011; 1(7):608-625.
20. Bashyam MD, Bair R, Kim YH, Wang P, Hernandez-Boussard T, Karikari CA, Tibshirani R, Maitra A and Pollack JR. Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia. 2005; 7(6):556-562.
21. Natsume H, Shinmura K, Tao H, Igarashi H, Suzuki M, Nagura K, Goto M, Yamada H, Maeda M, Konno H, Nakamura S and Sugimura H. The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer. J Transl Med. 2012; 10:97.
22. Kurzrock R and Stewart DJ. Equipoise abandoned? Randomization and clinical trials. Ann Oncol. 2013; 24(10):2471-2474.
23. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25(15):1960-1966.
24. Dienstmann R, Rodon J, Barretina J and Tabernero J. Genomic medicine frontier in human solid tumors: prospects and challenges. J Clin Oncol. 2013; 31(15):1874-1884.
25. Guha M. Novartis' lung cancer ALK inhibitor approved. Nature biotechnology. 2014; 32(7):607.
26. Shaw AT and Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 370(26):2537-2539.
27. Chabner BA. Early accelerated approval for highly targeted cancer drugs. N Engl J Med. 2011; 364(12):1087-1089.
28. Chee CE, Krishnamurthi S, Nock CJ, Meropol NJ, Gibbons J, Fu P, Bokar J, Teston L, O'Brien T, Gudena V, Reese A, Bergman M, Saltzman J, Wright JJ, Dowlati A and Brell J. Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas. Oncologist. 2013; 18(10):1091-1092.
29. Messersmith WA, Rajeshkumar NV, Tan AC, Wang XF, Diesl V, Choe SE, Follettie M, Coughlin C, Boschelli F, Garcia-Garcia E, Lopez-Rios F, Jimeno A and Hidalgo M. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Mol Cancer Ther. 2009; 8(6):1484-1493.
30. Guris DL, Fantes J, Tara D, Druker BJ and Imamoto A. Mice lacking the homologue of the human 22q11.2 gene CRKL phenocopy neurocristopathies of DiGeorge syndrome. Nat Genet. 2001; 27(3):293-298.
31. Bell ES and Park M. Models of crk adaptor proteins in cancer. Genes Cancer. 2012; 3(5-6):341-352.
32. Westin JR and Kurzrock R. It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. Mol Cancer Ther. 2012; 11(12):2549-2555.
33. Infante J, Somer, B., Park, J., et al. A randomized, doubleblind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2012; 30(Suppl 34; abstr 291).
34. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321(5897):1801-1806.
35. Chang DK, Grimmond SM and Evans TR. Mining the genome of exceptional responders. Nature Reviews Cancer. 2014; 14:291-292.
36. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M, Sander C, Socci ND, Ostrovnaya I, Viale A, Heguy A, Peng L, Chan TA, Bochner B, Bajorin DF, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012; 338(6104):221.
37. Young G, Wang K, He J, Otto G, Hawryluk M, Zwirco Z, Brennan T, Nahas M, Donahue A, Yelensky R, Lipson D, Sheehan CE, Boguniewicz AB, Stephens PJ, Miller VA and Ross JS. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. Cancer Cytopathol. 2013; 121(12):688-694.
38. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P, Sun J, Juhn F, Brennan K, Iwanik K, Maillet A, Buell J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nature biotechnology. 2013; 31(11):1023-1031.